Mirum Pharamceuticals (MIRM) PT Raised to $44 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MIRM Hot Sheet
Price: $96.97 +11.42%
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
16 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Baird analyst Brian Skorney raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $44.00 (from $39.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mirum Pharmaceuticals (MIRM) PT Raised to $202 at H.C. Wainwright
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
- Capital One Financial (COF) Declares $0.80 Quarterly Dividend; 1.6% Yield
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Robert W Baird, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
